TOMA Biosciences Releases the COMPASSTM Tumor Profiling System

By March 30, 2017Press Releases

Foster City, CA, March 30, 2017

A Complete End-to-End Tumor Profiling System for Cancer Genomics

TOMA Biosciences launches the COMPASSTM Tumor Profiling System – a simple and efficient workflow pathway from tumor, library preparation, sequencing, data analysis, clinical annotation, through reporting. Now, clinical researchers have everything they need to find clinically meaningful changes in tumor DNA.

The core of the COMPASSTM Tumor Profiling System is the Oligo Selective Sequencing capture assay, TOMA OS-Seq™, a patented technology invented at Stanford University. TOMA OS-Seq delivers unparalleled uniform sequence data of cancer genes from damaged DNA present in FFPE tumor specimens. The core offering of COMPASSTM allows the capture of tumor DNA from 130 cancer genes and can be customized to any genes of interest.

The COMPASSTM Tumor Profiling System includes:

  • a comprehensive set of DNA library preparation reagents
  • reference materials to assess sensitivity and specificity for validation
  • proprietary sequence data analysis software for somatic variant identification
  • options for annotation and reporting

COMPASSTM data analysis is performed through TOMA Stratus™. Stratus is a simple to use, cloud-based service with a web interface to easily upload data and download results. Within Stratus, COMPASSTM Analysis uses a proprietary method constructed to identify changes specific to the tumor DNA and removes inherited changes that many laboratories report without a specific somatic link.

COMPASSTM is a complete solution for clinical researchers looking to implement cancer genomics with superior performance while reducing cost and complexity.

“Our team set out to build a simple and complete solution for clinical researchers to analyze tumor DNA and produce actionable findings; with COMPASSTM they have achieved that aim.” said Wolfgang Daum, TOMA President and CEO.

“Finally, clinical researchers have what they need to simplify operations, improve accuracy and reduce costs. COMPASSTM can be implemented by clinical researchers and validation-ready in under a week.” commented Dr. Daum.

In addition to the core offering which includes the reagents, reference materials, and secondary analysis software, COMPASSTM enables several downstream interpretation options for clinical researchers, including access to curated clinical annotation information and reporting tools.

“FOR RESEARCH USE ONLY”

To learn more: watch ‘From Tumor to Action’ webinar.

Read more at www.prweb.com